Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.03 EUR | +1.75% | -0.98% | +7.69% |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 15.3M 16.42M | Sales 2025 * | 17.4M 18.67M | Capitalization | 30.27M 32.48M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.07M | Net income 2025 * | 2M 2.15M | EV / Sales 2024 * | 1.43 x |
Net cash position 2024 * | 8.4M 9.01M | Net cash position 2025 * | 10M 10.73M | EV / Sales 2025 * | 1.17 x |
P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
15.3
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.47% |
1 day | +1.15% | ||
1 week | -0.98% | ||
Current month | +1.50% | ||
1 month | +6.01% | ||
3 months | +6.56% | ||
6 months | +6.01% | ||
Current year | +7.69% |
Managers | Title | Age | Since |
---|---|---|---|
Jussi Hahtela
CEO | Chief Executive Officer | 51 | 21-06-03 |
Jussi Sorvo
DFI | Director of Finance/CFO | 34 | 20-12-31 |
Panu Hendolin
CTO | Chief Tech/Sci/R&D Officer | 53 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 23-06-13 | |
Founder | 81 | 87-12-31 | |
Director/Board Member | 73 | 19-04-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.03 | +1.75% | 2 433 |
24-04-25 | 1.995 | -0.75% | 985 |
24-04-24 | 2.01 | -0.50% | 2,634 |
24-04-23 | 2.02 | -0.98% | 22,615 |
24-04-22 | 2.04 | -0.49% | 8,953 |
Delayed Quote Nasdaq Helsinki, April 26, 2024 at 03:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.69% | 32.43M | |
-4.19% | 4.59B | |
-8.27% | 2.87B | |
+1.11% | 2.06B | |
-29.29% | 1.08B | |
-11.19% | 804M | |
-14.06% | 752M | |
-25.05% | 736M | |
-57.92% | 665M | |
-26.32% | 656M |
- Stock Market
- Equities
- BIOBV Stock